Amneal Makes It Three With Pegfilgrastim Approval
Third US Biosimilar Fylnetra Follows FDA Nods For Filgrastim And Bevacizumab
Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.
